Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Human myotubularin-related protein 9 regulates ER-to-Golgi trafficking and modulates WNT3A secretion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A programmed wave of uridylation-primed mRNA degradation is essential for meiotic progression and mammalian spermatogenesis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hepatitis B virus upregulates host microRNAs that target apoptosis-regulatory genes in an in vitro cell model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Novel Clinical and Radiological Findings in a Family with Autosomal Recessive Omodysplasia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clinical and histopathological predictors of outcome in malignant meningioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Glioblastoma multiforme (GBM) is the most common, and most aggressive primary brain tumor among adults. A vast majority of the tumors express high levels of the epidermal growth factor receptor (EGFR) as a consequence of gene amplification. Furthermore, gene amplification is often associated with mutation of EGFR, and the constitutive activated deletion variant EGFRvIII is the most common EGFR mutation found in GBM. Activated EGFR signaling, through overexpression and/or mutation, is involved in increased tumorigenic potential. As such, EGFR is an attractive target for GBM therapy. However, clinical studies with EGFR inhibitors have shown inconsistent results, and as such, further knowledge regarding the role of EGFR and EGFRvIII in GBM is needed. For this, an appropriate in vivo/in vitro tumor model is required. Here, we report the establishment of an experimental GBM model in which the expressions of EGFR and EGFRvIII are maintained both in xenograft tumors growing subcutaneously on mice and in cell cultures established in stem cell conditions. With this model it will be possible to further study the role of EGFR and EGFRvIII, and response to targeted therapy, in GBM.
OriginalsprogEngelsk
TidsskriftExperimental Cell Research
Vol/bind317
Udgave nummer11
Sider (fra-til)1513-26
Antal sider14
ISSN0014-4827
DOI
StatusUdgivet - 1 jul. 2011

ID: 32428052